[A20-87] Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2021
Project no.:
A20-87
Commission:
Commission awarded on 28.09.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
| First-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) |
Result of dossier assessment:
| Men: hint of considerable added benefit; women: hint of non-quantifiable, at most considerable added benefit |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A18-69 | Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-19 | Durvalumab (small cell lung cancer) - Addendum to Commission A20-87 | Commission completed |
| G21-07 | Durvalumab (small cell lung cancer) - Addendum to Commission A20-87 | Commission completed |
| A23-138 | Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-27 | Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-26 | Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-31 | Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-04-01 G-BA decision was published.